Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01175135 · ClinicalTrials.gov registry record · Phase 2
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
A Phase 2 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 259
- Enrollment target
NCT01175135 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 259 participants.
The verdict
NCT01175135, a Phase 2 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 259 participants
- Enrollment target
Study Summary
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period. The study will use the Positive and Negative Syndrome Scale (PANSS) to measure change in symptoms for PF-02545920 compared to risperidone and placebo treatment.
Interventions
- DRUG Placebo
- DRUG Risperidone
- DRUG PF-02545920
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01175135
The ClinicalTrials.gov registry entry for NCT01175135 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 259 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01175135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01175135 about?
NCT01175135 is a clinical study titled "An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia". This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period. The study will use the Positive and Negative Syndrome Scale (PANSS) to measure change in symptoms for PF-02545920 compared to risp...
What is the current status of trial NCT01175135?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 259 participants. The study started on 2010-10. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01175135?
The interventions under investigation include: Placebo (DRUG), Risperidone (DRUG), PF-02545920 (DRUG).
Who is sponsoring clinical trial NCT01175135?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.